Goldman Sachs Group Inc Mi Nk Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 17,561 shares of INKT stock, worth $12,819. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,561
Previous 15,632
12.34%
Holding current value
$12,819
Previous $14,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding INKT
# of Institutions
34Shares Held
912KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA234KShares$170,9520.0% of portfolio
-
Longbow Finance Sa Lutry, V8167KShares$121,6660.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny128KShares$93,3230.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.3KShares$70,3330.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$63,6530.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $24.7M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...